Compare Canadian Natural Resources Ltd. (CNQ) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Canadian Natural Resources Ltd. vs Citius Pharmaceuticals Inc — how do they compare? Canadian Natural Resources Ltd. trades at $47.75 (market cap $98.11B), while Citius Pharmaceuticals Inc trades at $0.75 (market cap $20.01M). The key difference: Canadian Natural Resources Ltd. is far larger — about 4903× Citius Pharmaceuticals Inc's market cap, and Canadian Natural Resources Ltd. pays a 3.73% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CNQ | CTXR | |
|---|---|---|
Market Cap | $98.11B | $20.01M |
Sector | Energy | Health |
52-Week High | $50.55 | $1.82 |
52-Week Low | $29.31 | $0.48 |
Enterprise Value | $108.54B | $16.23M |
Dividend Yield | 3.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Canadian Natural Resources (CNQ) trades at $47.845, up 1.26% today, with a bullish technical signal and strong earnings momentum after Q2 2026 EPS beat estimates. The company shows robust profitability with a 22.87% net margin and 26.69% ROE, supported by record production and disciplined capital spending. Recent news highlights dividend reliability and operational strength, with analyst consensus heavily favoring buy ratings.
CNQ presents a compelling investment case with attractive valuation (P/E 11.82), consistent dividend payouts, and positive cash flow trends. Key risks include oil price volatility and rising debt levels, but the company's scale and efficiency underpin resilience. Wall Street optimism, with 27 buy ratings, suggests further upside potential amid stable energy demand.
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Canadian Natural Resources Ltd.
Canadian Natural Resources is one of the largest oil and natural gas producers in western Canada, supplemented by operations in the North Sea and Offshore Africa. The company's portfolio includes light and medium oil, heavy oil, bitumen, synthetic oil, natural gas liquids, and natural gas. Production averaged 1.16 million barrels of oil equivalent per day in 2020, and the company estimates that it holds over 11.5 billion boe of proven and probable crude oil and natural gas reserves.
Read more on CNQ →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
